<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03469934</url>
  </required_header>
  <id_info>
    <org_study_id>ANB020-004</org_study_id>
    <nct_id>NCT03469934</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma</brief_title>
  <official_title>Placebo Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnaptysBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AnaptysBio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study will also assess the safety and tolerability of ANB020 in adult&#xD;
      patients with severe eosinophilic asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, proof of concept study&#xD;
      to assess the safety and tolerability of ANB20 in adult patients with severe eosinophilic&#xD;
      asthma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2017</start_date>
  <completion_date type="Actual">October 29, 2018</completion_date>
  <primary_completion_date type="Actual">October 29, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of ANB020 in adult patients with severe eosinophilic asthma: Number of participants with treatment-related adverse events as assessed by CTCAE v. 4.0</measure>
    <time_frame>Through study completion, Day 127</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v. 4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood eosinophil count</measure>
    <time_frame>Through study completion, Day 127</time_frame>
    <description>Monitor peripheral blood eosinophil counts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in respiratory assessments</measure>
    <time_frame>Through study completion, Day 127</time_frame>
    <description>Monitor FEV1 variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe Limited Pharmacokinetics: Cmax</measure>
    <time_frame>Throughout study, Day 64</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe Limited Pharmacokinetics: Time to Cmax</measure>
    <time_frame>Throughout study, Day 64</time_frame>
    <description>Time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test for immunogenicity</measure>
    <time_frame>Through study completion, Day 127</time_frame>
    <description>Detection of ADA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Eosinophilic Asthma</condition>
  <arm_group>
    <arm_group_label>ANB020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANB020, administration of ANB020</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, administration of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANB020</intervention_name>
    <description>ANB020</description>
    <arm_group_label>ANB020</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients aged ≥18 to ≤65 years and able to give informed consent.&#xD;
&#xD;
          -  Patients with a confirmed clinical diagnosis of eosinophilic asthma&#xD;
&#xD;
          -  History of diagnosis of eosinophilic asthma&#xD;
&#xD;
          -  Severe asthma diagnosed according to the Global Initiative for Asthma (GINA) 2016&#xD;
&#xD;
          -  Body mass index (BMI) of 18 to 38 kg/m2 (inclusive) and total body weight &gt;50 kg (110&#xD;
             lb.).&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test at screening&#xD;
             and be willing to use effective methods of contraception throughout the study.&#xD;
&#xD;
          -  Male patients must be willing to use effective methods of contraception during the&#xD;
             entire study period.&#xD;
&#xD;
          -  Patient must be on high dose ICS plus LABA.&#xD;
&#xD;
          -  Willing and able to comply with the study protocol requirements.&#xD;
&#xD;
          -  Have the ability to read and understand the study procedures and can communicate&#xD;
             meaningfully with the Investigator and staff.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have concomitant medical condition(s) which may interfere with the Investigator's&#xD;
             ability to evaluate the patient's response to the IP.&#xD;
&#xD;
          -  Have experienced severe life threatening anaphylactic reactions.&#xD;
&#xD;
          -  Have received any IP within a period of 3 months or 5 half lives of an IP&#xD;
&#xD;
          -  Have received high dose systemic corticosteroids&#xD;
&#xD;
          -  Have received treatment with biologics within 3 months or 5 half lives (whichever is&#xD;
             longer) before screening.&#xD;
&#xD;
          -  Abnormal ECG assessment at screening&#xD;
&#xD;
          -  Uncontrolled hypertension, or acute ischemic cardiovascular diseases.&#xD;
&#xD;
          -  If female, is pregnant or lactating, or intend to become pregnant during the study&#xD;
             period.&#xD;
&#xD;
          -  History (or suspected history) of alcohol or substance abuse within 2 years before&#xD;
             screening.&#xD;
&#xD;
          -  Any comorbidity that the Investigator believes is a contraindication to study&#xD;
             participation.&#xD;
&#xD;
          -  Have any other physical, mental, or medical conditions which, in the opinion of the&#xD;
             Investigator, make study participation inadvisable or could confound study&#xD;
             assessments.&#xD;
&#xD;
          -  Planned surgery during the study or 30 days before screening.&#xD;
&#xD;
          -  History of malignancy within 5 years, except non melanoma skin cancer which has been&#xD;
             fully treated with no current active disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Londei, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>AnaptysBio, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Midwest Allergy Sinus Asthma</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary &amp; Critical Care Specialists</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OK Clinical Research, LLC</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Center of Southern Oregon</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M239Q</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

